Somatrogon in paediatric growth hormone deficiency: a profile of its use in the EU

  

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest  E.S. Kim is a contracted employee of Adis International Ltd/Springer Nature and declares no conflicts of interest. Z.T. Al-Salama, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content. 

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable

Additional information about this Adis Drug Review can be found here

Abstract

Somatrogon (NGENLA®), a modified long-acting form of recombinant human growth hormone (rhGH), is a valuable new option for the treatment of paediatric patients aged ≥ 3 years with growth disturbance due to insufficient GH secretion in the EU, and offers the convenience of once-weekly administration. In a phase 3 randomized trial, once-weekly somatrogon was non-inferior to once-daily somatropin (rhGH; standard therapy) in increasing height velocity in paediatric patients with GH deficiency (GHD). Once-weekly somatrogon was associated with a lower treatment burden than once-daily somatropin in another phase 3 randomized trial. Somatrogon is generally well tolerated, with injection site pain being the most frequent treatment-emergent adverse event. Somatrogon is available as a multi-dose prefilled pen for subcutaneous injection.

© Springer Nature Switzerland AG 2022